Policy

Latest News

Most Favored Nation | Image Credit: © AliFuat-stock.adobe.com
Unpacking the Complexity of the Most Favored Nation Mandate

September 12th 2025

In a recent webinar, experts explored the Most Favored Nation mandate’s implications on drug pricing, patient access, and pharmaceutical innovation.

340B PVP spedning increased by nearly $37 million dollars from 2010 to 2021 due to eligibility expanision and market trends. | Image Credit: @onephoto - stock.adobe.com.jpeg
340B Program Spending Increases Due to Market Trends and Eligibility Expansion

September 11th 2025

FDA Approved. | Image Credit: wladimir1804 - stock.adobe.com .jpeg
FDA Issues Warning Letters Cracking Down on Misleading Drug Advertisements

September 10th 2025

Stagnation in Reimbursement Keeps Biomedical Innovation From Reaching All Patients, COA Panel Says
Stagnation in Reimbursement Keeps Biomedical Innovation From Reaching All Patients, COA Panel Says

September 9th 2025

AJMC commentary
State Restrictions on Prior Authorization

September 5th 2025

More News

AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo